Phase 3 Hypertension Trial, Recruiting NCT06804161 Sponsor: Prof. Dr. med. Ingo Eitel Condition: Hypertension
Back to Hypertension

Phase 3 Hypertension Trial, Recruiting

NCT06804161
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 60 years or older
  • People with high blood pressure — either newly diagnosed (confirmed by two separate measurements on different days showing systolic pressure above 140 mmHg or diastolic pressure above 90 mmHg), or previously diagnosed (confirmed by one measurement at the screening visit)
  • People who have had at least one past heart or blood vessel event, such as a heart attack, stroke, stable angina, diagnosed coronary heart disease, peripheral arterial disease, or a mini-stroke (TIA) — note: heart attacks or strokes that happened within the last 3 months do not count
  • OR, instead of a past heart or blood vessel event, people who have at least one cardiovascular risk factor, such as: currently smoking more than one cigarette per day for at least one year; high LDL cholesterol (above 4.0 mmol/L); being aged 75 or older; a high cardiovascular risk score (ESC HeartScore above 15%); or a BMI above 32 kg/m²

Who may not be able to join:

  • People whose high blood pressure is caused by another known medical condition
  • People who have had a heart attack or stroke within the past 3 months
  • People with heart failure with symptoms
  • People with a history of diabetes
  • People with a history of ketoacidosis (a serious chemical imbalance in the body)
  • People with significant liver problems (based on specific blood test results)
  • People with significantly reduced kidney function (based on a specific kidney function score at the first visit)
  • People who have taken an SGLT2 inhibitor medication within 8 weeks before joining the trial, or who have not tolerated this type of medication in the past
  • People who are currently participating in another clinical trial involving an investigational treatment within the last month
  • People with a known allergy or sensitivity to SGLT2 inhibitor medications
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
  • People with a serious medical condition (unrelated to kidney or heart/blood vessel disease) that a doctor estimates gives them a life expectancy of less than 2 years
  • People with an active cancer currently requiring treatment (with the exception of certain successfully treated skin cancers)
  • People who are unable to give informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ingo Eitel, Prof. Dr., Universitätsklinikum Schleswig-Holstein - Campus Lübeck

Phone: 045150044542

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Prof. Dr. med. Ingo Eitel
Registry
ClinicalTrials.gov
Start date
10 December 2025
Est. completion
30 May 2032

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Time until first occurrence of

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov